- Holland's Bear Advice: Buy the Survivors
- Analyst Picks: Three Resilient Retailers
- Ford Options Rev on Possible Volvo Deal
- BlackRock's Doll: Win With Last Week's Laggards
- Lucky 13? Bakers' Dozen Stock Picks
- Stock Picker: Time To Buy Value (Pt. 2)
- Stock Picker: Time To Buy Value (Pt. 1)
- Luxury Tech Stocks at Knock-Off Prices
- Options Action: Traders Bet on Potash
- Travel Stocks as a Value Play
- Holland's Bear Advice: Buy the Survivors
- Cramer's Outrage: Paulson & Bernanke
- Lightning Round: Genzyme, Goldman Sachs, U.S. Steel and More
- Lightning Round OT: Verizon, Kroger, Novartis and More
- Executive Decision: Foster Wheeler CEO Ray Milchovich
- Cavs Owner Doesn't Mind Buzz Over James
- Trading Obama's Stimulus Plan
- What Bailouts?
- Your First Move For Tuesday December 2nd
- Web Extra: Fast & Furious Trades For Tuesday
- Toyota to Cut Bonuses Amid Reports of Output Cuts
- China Eyes Consumer Boost, May Aim 8% 2009 Growth
- Australia Retail Sales Rise No Bar to Sharp Rate Cut
- Asia Slides on Economic Woes, Nikkei Slumps 6.4%
- Beyond Rate Cuts: Other Fed Tools Against Downturn
- Paulson's Speech on the Economy and Financial System
- Paulson: US Weighs Other Uses for the Bailout Fund
- House Democrats May Seek $500 Billion Stimulus
- Bernanke's Speech to the Austin Chamber of Commerce
Text Size 
Size doesn't necessarily matter when it comes to five-star investing. Just ask Frank Sustersic, portfolio manager for Turner Investment Partners.
His small-cap Turner Emerging Growth Fund is up an average of 16.40 percent per year over the last five years. It's currently closed to new investors, but Sustersic is willing to share some of his favorite names.
Recommendations:
Some of his favorite stocks are clinical-research organizations, or CROs.
"They help pharmaceutical companies conduct clinical-research trials," he told CNBC. "All of the companies right now have an amazing tailwind...and currently, there is a pretty significant outsourcing trend that's occurring; pharmaceutical and biotech companies are trying to change their cost structure to be more flexible."
Two of those CROs are Parexel
[PRXL
Loading...
()
] and Icon
[ICLR
Loading...
()
].
"Over the next three to six months, the stocks could need to consolidate a bit," he cautioned, but added, "Over the long-term period of time, I'm still optimistic about these stocks."
Sustersic also likes Ansys
[ANSS
Loading...
()
].
"Ansys makes (simulation) software used by engineers in product designs," he said. "They have a subscription model, so about 70 percent of their revenue base is recurring via subscription or licensing and maintenance."
(Contd.)
____________________________________
CNBC Stock Intelligence:
____________________________________
He's also enthusiastic about Willbros Group
[WG
Loading...
()
], a producer of large-diameter pipeline for natural-gas and oil companies.
"They recently got some big contract wins up in Canada," he noted. "They're probably sold out for the next year or so."
Rounding out his list -- and maybe, saving the best for last -- is Deckers Outdoor
[DECK
Loading...
()
], maker of the popular UGG brand boots.
"Very controversial, very volatile stock," he said, "It still looks like fantastic visibility going forward."
He said an informal survey of department-store buyers revealed that UGGs was the only apparel or shoe product that really sold well during the last holiday-shopping season.
"If anything, they regretted not ordering more," he said.
Disclosures:
Disclosure information for Frank Sustersic was not immediately available.
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes